Busulfan
- Generic Name
- Busulfan
- Brand Names
- Busulfex, Myleran, Busulfan Fresenius Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C6H14O6S2
- CAS Number
- 55-98-1
- Unique Ingredient Identifier
- G1LN9045DK
- Background
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According t...
- Indication
For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing...
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Ruxolitinib in Combination With Autotransplant
- Conditions
- Interventions
- First Posted Date
- 2015-06-12
- Last Posted Date
- 2016-08-12
- Lead Sponsor
- Marina Kremyanskaya
- Registration Number
- NCT02469974
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT02441803
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)
- First Posted Date
- 2015-04-07
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT02410551
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT)
- First Posted Date
- 2014-12-08
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- University College, London
- Target Recruit Count
- 11
- Registration Number
- NCT02310997
- Locations
- 🇬🇧
Nottingham City Hospital, Nottingham, United Kingdom
🇬🇧Bristol Haematology & Oncology Centre, Bristol, United Kingdom
🇬🇧University College London Hospital, London, Greater London, United Kingdom
Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
- Conditions
- Interventions
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2018-01-16
- Lead Sponsor
- Ivan S Moiseev
- Target Recruit Count
- 200
- Registration Number
- NCT02294552
- Locations
- 🇷🇺
First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russian Federation
Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide
- First Posted Date
- 2014-11-05
- Last Posted Date
- 2020-05-12
- Target Recruit Count
- 7
- Registration Number
- NCT02282904
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
- Conditions
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: BusulfanDrug: CyclophosphamideDrug: Fludarabine PhosphateOther: Laboratory Biomarker AnalysisDrug: MelphalanDrug: MethotrexateDrug: Mycophenolate MofetilDrug: RuxolitinibDrug: TacrolimusRadiation: Total-Body IrradiationProcedure: Umbilical Cord Blood Transplantation
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 61
- Registration Number
- NCT02251821
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 116
- Registration Number
- NCT02250937
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 27
- Registration Number
- NCT02248597
- Locations
- 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- First Posted Date
- 2014-05-21
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 70
- Registration Number
- NCT02143830
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.